Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.33 |
| ▸ | CA9 | Q16790 | 7/20 | 0.33 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | PYGB | P11216 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | IDUA | P35475 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13471605 | 1.00 | CA12 (0.33) | CA12CA9CA1CA2CA4 | |
| SCHEMBL9915141 | 0.79 | FUCA1 (0.37) | CA12CA9CA2IDUA | |
| SCHEMBL19215368 | 0.79 | L3MBTL1 (0.35) | OGA | |
| SCHEMBL13471588 | 0.79 | FUCA1 (0.37) | CA12CA9CA2IDUA | |
| SCHEMBL14447610 | 0.79 | OGA (0.41) | OGAPYGBGAAFBP1G6PD | |
| SCHEMBL12972236 | 0.79 | OGA (0.41) | OGAPYGBGAAFBP1G6PD | |
| SCHEMBL13575271 | 0.79 | OGA (0.41) | OGAPYGBGAAFBP1G6PD | |
| SCHEMBL14447602 | 0.79 | OGA (0.41) | OGAPYGBGAAFBP1G6PD | |
| SCHEMBL12899923 | 0.77 | FUCA1 (0.34) | CA12CA9CA2 | |
| SCHEMBL16134528 | 0.75 | OGA (0.33) | OGAPYGBGAAIDUAFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007712-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2017-01-12 | — | — | US | disclosed |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-07 | — | — | US | disclosed |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK AS (DK) | 2015-12-03 | — | — | US | disclosed |
| US-8853161-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-20120220517-A1 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | NOVO NORDISK A/S (DK) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | CA12 1149/4885CA9 791/4885CA1 2921/4885 |
| US-20120220517-A1 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | PTMS, ANPEP, NGLY1 | CA12 605/4885CA9 1898/4885CA1 1855/4885 |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | CA12 1149/4885CA9 791/4885CA1 2921/4885 |
| US-20170007712-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | CA12 605/4885CA9 1898/4885CA1 1855/4885 |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | CA12 605/4885CA9 1898/4885CA1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.